Medical device company Dynatronics Corporation (NASDAQ:DYNT) disclosed on Tuesday its net income of USD14,000 for Q2 fiscal 2018 ended 31 December 2017.
This is compared with a net loss of USD95,000 for the quarter ended 31 December 2016.
Net sales of USD18.1m were recorded for the Q2 fiscal 2018 ended 31 December 2017, up 107.5% over net sales of USD8.7m in the same period of the prior year.
Gross profit of USD5.8m was announced for the Q2 fiscal 2018 ended 31 December 2017, a rise of 87.7% versus USD3.1m the same prior year quarter.
The company added that the rise in net sales, gross profit and net income were attributable to its acquisitions of Hausmann and Bird & Cronin in the past year.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system